LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease

(2018) Peter A. LeWitt et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats

(2018) Michael Aagaard Andersen et al.   TOXICOLOGY

LRRK2 activation in idiopathic Parkinson’s disease

(2018) Roberto Di Maio et al.   Science Translational Medicine

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

(2017) Jack D. Scott et al.   JOURNAL OF MEDICINAL CHEMISTRY

A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci

(2017) Diana Chang et al.   NATURE GENETICS

Parkinson disease

(2017) Werner Poewe et al.   Nature Reviews Disease Primers

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

(2016) Martin Steger et al.   eLife

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

(2015) Reina N. Fuji et al.   Science Translational Medicine

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

(2014) Mike A Nalls et al.   NATURE GENETICS

Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis

(2014) Pika Miklavc et al.   PLoS One

Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment

(2014) Nanjun Liu et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

(2013) Anthony A. Estrada et al.   JOURNAL OF MEDICINAL CHEMISTRY

The genetics of Parkinson's disease: Progress and therapeutic implications

(2013) Andrew B. Singleton et al.   MOVEMENT DISORDERS

The current and projected economic burden of Parkinson's disease in the United States

(2013) Stacey L. Kowal et al.   MOVEMENT DISORDERS

Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis

(2013) Daniel Ness et al.   PLoS One

Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

(2013) Marco A. S. Baptista et al.   PLoS One

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

(2012) Anthony A. Estrada et al.   JOURNAL OF MEDICINAL CHEMISTRY

Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway

(2012) Youren Tong et al.   Molecular Neurodegeneration

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

(2011) Martin C. Herzig et al.   HUMAN MOLECULAR GENETICS

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

(2010) Nicolas Dzamko et al.   BIOCHEMICAL JOURNAL

Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities

(2010) Elizabeth A Tengstrand et al.   Expert Opinion on Drug Metabolism & Toxicology

Biological Function of the Cellular Lipid BMP—BMP as a Key Activator for Cholesterol Sorting and Membrane Digestion

(2010) Hichem D. Gallala et al.   NEUROCHEMICAL RESEARCH

Effect of lysosomal storage on bis(monoacylglycero)phosphate

(2008) Peter J. Meikle et al.   BIOCHEMICAL JOURNAL

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY